Hi cal. Sorry for the delayed response. I'm a little busy this week but I will look it over this weekend when I have some time.
Maybe by the next annual meeting he will be gone. You do realize he received over 3.6M "NAY" votes of the ~19M votes cast last May, significantly more than anyone else. There are others who agree with us but unfortunately there is no major stakeholder to drive him out. We little guys can't do a thing.
Nothing posted by me on this thread is a lie. Look up the facts. The only liar was allo who has been busy this morning removing posts.
Why? Because if you were looking for a new CEO, would you pick someone who ran companies to the ground or a candidate that has a proven track record of successful leadership? I don't believe Zami is qualified as do 15% of the shareholders who voted against him in the last shareholders' meeting.
AN ATM IS NOT A SHELF. The ATM was pursuant to the shelf effective October 2011. An ATM agreement can only be entered upon if there is a valid Form S-3 allowing the issuance of new shares. THEY ARE DIFFERENT.
Form S-3 from SEC website:
PRELIMINARY PROSPECTUS (Subject to Completion)
Dated September 26, 2011
PLURISTEM THERAPEUTICS INC.
We may from time to time sell common stock, preferred stock and warrants to purchase common stock, and units of two or more of such securities, in one or more offerings for an aggregate initial offering price of $150,000,000. We refer to the common stock, the preferred stock, the warrants to purchase common stock and the units collectively as the securities.
Read the latest 10k. Page F-17 under Stockholder Equity:
"Following a shelf registration on Form S-3 filed and declared effective in October 2011, the Company entered in December 2012 into an At Market Issuance Sales Agreement (“ATM Agreement”) with an underwriter. On September 11, 2014, the Company notified the underwriter of the termination of the ATM Agreement."
Now who's the liar???
Effective September 2011 expired in October of this year. They are valid for 3 years, as are ATM's. Hence the termination of the MLV agreement. There were no new shares to sell until a new shelf registration went into effect. Don't think an ATM is a shelf as allo had stated. They are two different entities and an ATM can't be executed if there is no effective shelf.
Because the prior shelf expired in October!! Very simple.. Look it up.
According to Zami:
Hip replacement results will be presented later this year...
Preeclampsia trial will begin soon...
Rotator cuff trial to begin soon...
I didn't know about the little girl who passed, but I did know about the second patient who did...
We have plenty of cash...
The guy is continually blowing smoke.......
Hey, allo. How're Zami's former companies doing? Elbit Systems is trading at 16 cents. Robomatix was acquired for peanuts after trading on the OTCBB markets. Honestly, his resume for running companies isn't very impressive.
Zami says a lot of things. Buy he still won't talk to the investors.
Allo, are you serious! You just deleted that whole thread. You are really nothing more than a child. Grow up !!!!
Let's figure it out. PhAse 1 then Phase 2 then Phase 3. Followed by submission, then the FDA response. Hmmm. My guess no less than 6-8 years.
Great stuff. Thanks. The best and most informative post in weeks.
Good stuff cal. Thanks for keeping it real. I AM frustrated with the company. Not only is it the lack of information, but it is also the way the timelines aren't being fulfilled. Go back and read some of the analyst reports. Earlier in the year, certain milestones were expected 2H14, but today these same events are 1H15. It was only by chance that I discovered enrollment progression for the IC trial. This irked me as well as I was thinking it was closer to completion.
I was hoping for more data in the hip replacement trial as this is most likely the first catalyst to be expected. It's pretty much the only indication where we may see a partnership at this point. The United trial is another area we may see some results, but those aren't expected until late next year. And finally, why is the FDA dragging their feet with OD status and the trial design acceptance for preeclampsia?
As evidenced, there is plenty of potential here, but this is definitely a long term play. The information we need is results. I will begin to cost up when I see something concrete and not speculative. Until then, we sit and wait.
Regarding patents, as of today, they have only been granted 3 in the US, 2 in Europe, 3 in Australia, 2 each in Hong Kong & Singapore and 1 each in a couple other scattered countries.. The rest are still pending per the latest 10-K. Good stuff but a world away from allo touts.
As far as allo & buteo, go back and read some of buteo's posts from 2011. He has evolved into the more reasonable side of allo's group, but back then he could be as obnoxious. They work for the same company.
The time may eventually come, but right now patience is the key.
But doesn't Osiris have the world's first approved stem cell drug, remestemcel-L for graft versus host disease? Are they not currently generating revenue from this product? Seems to me they own this market. PSTI is many, many years away from even beginning to have any market share here.